Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/28/2025

PPI Dosing for Silent Reflux (Laryngopharyngeal Reflux)

  • The American Gastroenterological Association recommends twice-daily PPI dosing for 8-12 weeks for silent reflux, as once-daily dosing is insufficient for most patients with these symptoms 1, 2
  • Twice-daily PPI therapy is superior to once-daily dosing for extraesophageal reflux symptoms, with a standard approach of omeprazole 20 mg twice daily or lansoprazole 30 mg twice daily for 2-3 months 1, 2
  • The duration of treatment should be at least 8-12 weeks for empiric treatment of extraesophageal symptoms 1, 2

Evidence Supporting Twice-Daily Dosing

  • Twice-daily dosing achieves superior gastric acid suppression compared to once-daily dosing, with 54% of patients who failed once-daily PPI showing symptom improvement after switching to twice-daily dosing 1, 2
  • Omeprazole 20 mg twice daily or lansoprazole 30 mg twice daily may still allow nocturnal acid breakthrough in many patients, underscoring that fixed dosing may be inadequate 3, 4

Clinical Algorithm

  • The initial therapy for silent reflux with concomitant typical GERD symptoms should be twice-daily PPI, such as omeprazole 20 mg BID or lansoprazole 30 mg BID, for 8-12 weeks 1, 2
  • If isolated extraesophageal symptoms are present without typical GERD, evidence does not support empiric PPI therapy, and objective testing should be considered before treatment 1, 2

Important Caveats

  • Meta-analyses show limited PPI efficacy for extraesophageal symptoms, with no advantage over placebo for chronic laryngitis or chronic cough, although these studies included patients without confirmed GERD 1, 2
  • PPIs work best when patients have concomitant typical esophageal GERD symptoms and objective testing confirms pathologic reflux 1, 2

Dosing Specifics by Agent

  • The British Society of Gastroenterology guidelines support twice-daily PPI therapy as the standard, with at least 75% symptom reduction as the therapeutic goal 5, 6, 7